```
=> file caplus
FILE 'CAPLUS' ENTERED AT 10:55:23 ON 04 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 4 Jan 2007  VOL 146 ISS 2
FILE LAST UPDATED: 3 Jan 2007  (20070103/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d que
L1              STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L3          285 SEA FILE=REGISTRY SSS FUL L1
L4           14 SEA FILE=CAPLUS L3


=> d l4 1-14 ibib abs hitstr

L4   ANSWER 1 OF 14  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2006:680977  CAPLUS
DOCUMENT NUMBER:          145:145559
TITLE:                    Heteroaromatic quinoline compounds as
                          phosphodiesterase inhibitors, their preparation,
                          pharmaceutical compositions, and use in therapy
INVENTOR(S):              Verhoest, Patrick Robert; Helal, Christopher John;
                          Hoover, Dennis Jay; Humphrey, John Michael
PATENT ASSIGNEE(S):       Pfizer Products Inc., USA
SOURCE:                   PCT Int. Appl., 90 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2006072828         A2    20060713    WO 2005-IB3937          20051222
     WO 2006072828         A3    20061109
```

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2006154931	A1	20060713	US 2006-326221		20060105
NL 1030863	A1	20060710	NL 2006-1030863		20060106
PRIORITY APPLN. INFO.:			US 2005-642058P	P	20050107

OTHER SOURCE(S): MARPAT 145:145559

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to heteroaryl quinoline derivs. of formula I, which are phosphodiesterase (PDE) inhibitors, in some cases selective PDE-10 inhibitors. In compds. I, each R1 is independently selected from H, halo, OH, cyano, C1-8 alkyl, C2-8 alkenyl, C1-8 alkoxy, 4- to 7-membered heterocyclyl, etc.; p is 0-3; Het1 is (un)substituted mono- or bicyclic heteroaryl; Het2 is (un)substituted mono- or bicyclic heteroaryl, where Het2 is vicinal to the Ph ring on Het1; X1 and X2 are independently selected from O, S, (un)substituted N, and (un)substituted C, where are least one of X1 and X2 is C; and each Y is independently selected from N and (un)substituted C; provided that Het2 is not a tetrazole. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I, as well as to the use of the compns. for the treatment of neurodegenerative and psychiatric disorders, such as psychosis. Substitution of 2-(chloromethyl)quinoline with Me 4-hydroxybenzoate followed by hydrolysis and amidation gave Weinreb amide II, which underwent addition of deprotonated 4-methylpyridine to give ketone III. Condensation of III with N-(dimethoxymethyl)-dimethylamine and heterocyclization with hydrazine gave pyrazole IV. The compds. of the invention express IC50 values for PDE-10 inhibition of less than 10 μM (no specific data).

IT 898564-29-9P, 2-[[4-[2-(Pyridin-4-yl)ethynyl]phenoxy]methyl]quinoline

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of heteroaryl quinoline compds. as PDE inhibitors)

RN 898564-29-9 CAPLUS

CN Quinoline, 2-[[4-(4-pyridinylethynyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1240986 CAPLUS
DOCUMENT NUMBER: 144:22906
TITLE: Preparation of fused heterocycle kinase inhibitors for treatment of protein tyrosine kinase-related diseases
INVENTOR(S): Cusack, Kevin; Salmeron-Garcia, Jose-Andres; Gordon, Thomas D.; Barberis, Claude E.; Allen, Hamish J.; Bischoff, Agniezka K.; Ericsson, Anna M.; Friedman, Michael M.; George, Dawn M.; Roth, Gregory P.; Talanian, Robert V.; Thomas, Christine; Wallace, Grier A.; Wishart, Neil; Yu, Zhengtian
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 362 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005110410	A2	20051124	WO 2005-US16903	20050513
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2006074102	A1	20060406	US 2005-129624	20050513
PRIORITY APPLN. INFO.:			US 2004-571281P P	20040514

OTHER SOURCE(S): MARPAT 144:22906
GI



I



II

AB The invention is related to the preparation of fused heterocycles of formula I [A, B = independently N, S, O, a bond, etc.; D = C, N, S, O, C:C; U, V, W = independently CH and derivs., N; Y = a bond, CONH2 and derivs., SO, etc.; Z = H, halo, CN, etc.; X1 = a bond, halo, O, SO, NHSO2, etc.; R1 = a bond, (un)substituted benzofuranyl, benzimidazolyl, pyrrolyl, etc.; when R1 is not a bond, then X2 = a bond, O,S, NHCO and derivs., aliphatic group, etc.; or when R1 = a bond, then X2 = a bond and R2 is not a bond; R2 = a

bond or (un)substituted benzoxazolyl, Ph, etc.; with provisos; and with the exception of certain compds.], and their pharmaceutically acceptable salts as inhibitors of kinases, particularly COT or MK2 kinases. The invention is also related to the use of certain compds. I as inhibitors of angiogenic receptor tyrosine kinases. Thus, reacting 4-(3-aminophenyl)thieno[2,3-c]pyridine-2-carboxamide with cyclopropanecarboxaldehyde gave thienopyridine II. All compds. I significantly inhibit either COT or MK2 at concns. of 50 μM or below.

IT 870242-79-8P, 4-[[4-[(Pyridin-3-yl)ethynyl]phenyl]oxy]thieno[2,3-c]pyridine-2-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(COT kinase inhibitor; preparation of fused heterocycles as kinase inhibitors)

RN 870242-79-8 CAPLUS

CN Thieno[2,3-c]pyridine-2-carboxamide, 4-[4-(3-pyridinylethynyl)phenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1176932 CAPLUS

DOCUMENT NUMBER: 143:440271

TITLE: Preparation of alkynyl pyridine derivatives as MCH receptor antagonists

INVENTOR(S): Stenkamp, Dirk; Mueller, Stephan Georg; Lustenberger, Philipp; Lehmann-Lintz, Thorsten; Roth, Gerald Juergen; Schindler, Marcus; Thomas, Leo; Lotz, Ralf R. H.; Rudolf, Klaus

PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SOURCE: PCT Int. Appl., 179 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005103032	A2	20051103	WO 2005-EP3686	20050408
WO 2005103032	A3	20060202		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 102004017930	A1	20051103	DE 2004-102004017930	20040414
CA 2558755	A1	20051103	CA 2005-2558755	20050408
EP 1737824	A2	20070103	EP 2005-732062	20050408
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 2005245529	A1	20051103	US 2005-105010	20050413
PRIORITY APPLN. INFO.:			DE 2004-102004017930A	20040414
			US 2004-563631P P	20040420
			WO 2005-EP3686 W	20050408

OTHER SOURCE(S): MARPAT 143:440271

GI



I



II

AB Title compds. I [R1 and R2 independently = H, (un)substituted alkyl, cycloalkyl, etc. or R1 and R2 together form a (un)substituted alkylene bridge in which one CH2 group not adjacent to NR1R2 may be replaced by O, S, SO, etc.; X = (un)substituted alkylene bridge; W and Z independently = single bond or (un)substituted alkylene bridge in which two adjacent C-atoms may be connected to each other; Y and A independently = (un)substituted Ph, pyridinyl, pyrimidinyl, etc.; B = (un)substituted alkyl, alkenyl, alkynyl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as MCH receptor antagonists. Thus, e.g., II was prepared by Sonogashira coupling of 3-(4-iodo-phenyl)cyclohexanol (preparation given) with 5-(4-chloro-phenyl)-2-ethynyl-pyridine followed by mesylation and subsequent coupling with 3,5-dimethylpiperidine. The binding activity of I towards MCH-1 receptor was evaluated using scintillation assay and it was revealed that selected compds. of the invention possessed IC50 values in the range of 3.7 up to 25 nM. I as MCH receptor antagonist should prove useful in the treatment of diseases such as but not limited to bulimia, diabetes and obesity. Pharmaceutical compns. comprising I are disclosed.

IT 868608-73-5P 868608-75-7P 868608-78-0P
868608-81-5P 868608-82-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of alkynyl pyridine derivs. as MCH receptor antagonists)

RN 868608-73-5 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-methyl-2-(4-methyl-1-piperidinyl)propoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 868608-75-7 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[(2R)-2-(4-methyl-1-piperidinyl)propoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868608-78-0 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[(2S)-2-(4-methyl-1-piperidinyl)propoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868608-81-5 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[(2R)-3-methyl-2-(4-methyl-1-piperidinyl)butoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868608-82-6 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[(2S)-3-methyl-2-(4-methyl-1-piperidinyl)butoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 868609-65-8P 868609-68-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of alkynyl pyridine derivs. as MCH receptor antagonists)

RN 868609-65-8 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[(1R)-2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868609-68-1 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[(1S)-2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1155535 CAPLUS
DOCUMENT NUMBER: 143:422040
TITLE: Diarylalkyne compounds with MCH-receptor antagonistic activity, their preparation, pharmaceutical compositions, and use in therapy
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany
SOURCE: U.S. Pat. Appl. Publ., 62 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005239826	A1	20051027	US 2005-104915	20050413
DE 102004017935	A1	20051103	DE 2004-102004017935	20040414
CA 2559021	A1	20051103	CA 2005-2559021	20050408
WO 2005103031	A1	20051103	WO 2005-EP3683	20050408

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
DE 2004-102004017935A 20040414
US 2004-563677P P 20040420
WO 2005-EP3683 W 20050408

OTHER SOURCE(S): MARPAT 143:422040
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to alkyne compds. of general formula I, which are antagonists of melanin-concentrating hormone (MCH) receptors. In compds. I, R1 is selected from C3-6 alkenyl, C3-6 alkynyl, (hydroxy-C3-7 cycloalkyl)-C1-3 alkyl, oxa-C4-7 cycloalkyl, and dihydroxy-C3-7 alkyl, each optionally substituted; R2 is independently selected from H, (un)substituted C1-8 alkyl, (un)substituted C3-7 cycloalkyl, (un)substituted Ph, (un)substituted pyridinyl, etc., or R1 and R2, together with the N atom to which they are bound, form an (un)substituted heterocycle; X is (un)substituted C1-4 alkylene; W and Z are each independently a bond or a C1-2 alkylene; Y and A are each independently (un)substituted Ph, (un)substituted pyridinyl, (un)substituted pyrimidinyl, (un)substituted pyrazinyl, etc.; B is (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl, (un)substituted C3-7 cycloalkyl, (un)substituted Ph, (un)substituted pyridinyl, etc.; including tautomers, enantiomers, salts, and mixts. thereof, with 6 specific compds. excluded. The invention also relates to the preparation of I, pharmaceutical compns. containing I and one or more physiol. acceptable excipients, inert carriers or diluents, as well as to the use of the compns. for the treatment of metabolic disorders and/or eating disorders, particularly obesity and

diabetes. N-Alkylation of 3-methylpyridine with benzyl chloride followed by hydride reduction, asym. dihydroxylation, and debenzylation gave optically active piperidinediol II. 2-Bromoethanol underwent substitution with 4-iodo-2-methylphenol to give the corresponding ether, which was coupled with trimethylsilylacetylene and desilylated to give alkyne III. Coupling of III with 2,5-dibromopyridine, Suzuki coupling with 4-chlorophenylboronic acid, mesylation and substitution with piperidinediol II resulted in the formation of diarylalkyne IV. The compds. of the invention are MCH-receptor antagonists, with compound IV expressing an IC50 value of 10.9 nM.

IT 866928-10-1P, (3S,4R)-1-[2-[4-[[5-(4-Chlorophenyl)pyridin-2-yl]ethynyl]-2-(methyl)phenoxy]ethyl]-4-(trifluoromethyl)piperidine-3,4-diol 866928-11-2P 866928-37-2P, (3S,4R)-1-[2-[4-[5-(4-Chlorophenyl)pyridin-2-ylethynyl]phenoxy]ethyl]-4-trifluoromethylpiperidine-3,4-diol 866928-39-4P 866928-69-0P, (3R,4S)-1-[2-[4-[5-(4-Chlorophenyl)-3-fluoropyridin-2-ylethynyl]phenoxy]ethyl]-4-methylpiperidine-3,4-diol 866928-71-4P 866928-76-9P 866928-79-2P 868051-86-9P 868051-87-0P 868051-88-1P 868051-89-2P 868051-90-5P 868051-91-6P 868051-92-7P 868051-93-8P 868051-94-9P 868051-95-0P 868051-96-1P 868052-04-4P 868052-05-5P 868052-06-6P 868052-07-7P 868052-08-8P 868052-09-9P 868052-10-2P 868052-11-3P 868052-12-4P 868052-13-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of diarylalkynes as MCH-receptor antagonists)

RN 866928-10-1 CAPLUS

CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-(trifluoromethyl)-, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-11-2 CAPLUS

CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-(trifluoromethyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-37-2 CAPLUS
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-(trifluoromethyl)-, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-39-4 CAPLUS
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-(trifluoromethyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-69-0 CAPLUS
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-methyl-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-71-4 CAPLUS
CN Cyclopropanol, 1-[(2S)-1-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-76-9 CAPLUS
CN Cyclopropanol, 1-[(2S)-1-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-79-2 CAPLUS
CN Cyclopropanol, 1-[(2S)-1-[2-[2-bromo-4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868051-86-9 CAPLUS
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-methyl-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868051-87-0 CAPLUS
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-methyl-, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868051-88-1 CAPLUS
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-3-methyl-, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868051-89-2 CAPLUS
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-3-methyl-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868051-90-5 CAPLUS
CN 3,4-Pyrrolidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 868051-91-6 CAPLUS
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868051-92-7 CAPLUS
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868051-93-8 CAPLUS
CN 4-Piperidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 868051-94-9 CAPLUS
CN Cyclopropanol, 1-[(2S)-1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868051-95-0 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-α,α-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868051-96-1 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-hydroxy-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868052-04-4 CAPLUS
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-methyl-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868052-05-5 CAPLUS

CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-methyl-, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868052-06-6 CAPLUS
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-3-methyl-, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868052-07-7 CAPLUS
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-3-methyl-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868052-08-8 CAPLUS
CN 3,4-Pyrrolidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 868052-09-9 CAPLUS
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868052-10-2 CAPLUS
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868052-11-3 CAPLUS
CN 4-Piperidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 868052-12-4 CAPLUS
CN Cyclopropanol, 1-[(2S)-1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868052-13-5 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-α,α-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1146296 CAPLUS
DOCUMENT NUMBER: 143:430115
TITLE: Acetylene compound in smectic liquid crystal composition to improve various properties and liquid crystal display
INVENTOR(S): Ochi, Takahiko; Totani, Yoshiyuki
PATENT ASSIGNEE(S): Mitsui Chemicals Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 43 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005298453	A	20051027	JP 2004-121155	20040416

PRIORITY APPLN. INFO.: JP 2004-121155 20040416

GI



I

AB The title acetylene compound is represented by a general formula I (A = pyridine-2,5-diyl; B, C = 1,4-phenylene, trans-1,4-cyclohexylene, 2,6-naphthylene; R1 = C2-24-alkyl, C2-4-alkoxyalkyl, C2-24-unsatd. hydrocarbyl; R2 = C2-24-alkoxyalkyl; X1, X3 = single bond, -C.tplbond.C-, -O-, -COO-, -OCO-; X2 = single bond, -COO-, -OCO-; Y1, Y2 = H, halo; n = 0, 1). 5 Synthetic examples, 5 liquid crystal mixture examples, and 5 liquid crystal display examples are given.

IT 868379-91-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of acetylene compound; acetylene compound in smectic liquid crystal composition to improve various properties and liquid crystal display)

RN 868379-91-3 CAPLUS

CN Pyridine, 5-[[3-fluoro-4-[(tetrahydro-2H-pyran-2-yl)oxy]phenyl]ethynyl]-2-(nonyloxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1132924 CAPLUS

DOCUMENT NUMBER: 143:405812

TITLE: Preparation of substituted pyridine alkynes with MCH antagonistic activity for the treatment of metabolic disorders

INVENTOR(S): Stenkamp, Dirk; Mueller, Stephan Georg; Lustenberger, Philipp; Lehmann-Lintz, Thorsten; Roth, Gerald Juergen; Rudolf, Klaus; Schindler, Marcus; Thomas, Leo; Lotz, Ralf

PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany

SOURCE: U.S. Pat. Appl. Publ., 67 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 2005234101	A1	20051020	US 2005-104889	20050413
DE 102004017934	A1	20051103	DE 2004-102004017934	20040414
CA 2559688	A1	20051103	CA 2005-2559688	20050408
WO 2005103002	A2	20051103	WO 2005-EP3685	20050408
WO 2005103002	A3	20060202		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1737823	A2	20070103	EP 2005-737015 20050408

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

PRIORITY APPLN. INFO.:

DE 2004-102004017934A		20040414
US 2004-563590P	P	20040420
WO 2005-EP3685	W	20050408

GI



II

AB Various substituted pyridinyl alkynes are prepared For instance, 2-[[4-[[5-(4-chlorophenyl)pyridin-2-yl]ethynyl]-2-methylphenyl]oxy]ethyl methanesulfonate (I) is prepared in 6 steps from 4-iodophenol, 2-bromoethanol, trimethylsilylacetylene, 2,5-dibromopyridine and 4-chlorophenylboronic acid. This intermediate is reacted with a variety of amines to produce example compds. I is converted to II by displacement with the corresponding amine. II exhibits an IC50 = 6.2 nM for MCH-1. Example compds. are useful for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

IT 690265-45-3P 866929-02-4P 866929-03-5P
866929-04-6P 866929-05-7P 866929-06-8P
866929-16-0P 866929-19-3P 866929-27-3P
866929-35-3P 866929-42-2P 866934-41-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted pyridine alkynes with MCH antagonistic activity for treatment of metabolic disorders)

RN 690265-45-3 CAPLUS
CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 866929-02-4 CAPLUS
CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(4-methyl-1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 866929-03-5 CAPLUS
CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]ethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866929-04-6 CAPLUS
CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(4-hydroxy-1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 866929-05-7 CAPLUS

CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(2,6-dimethyl-1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 866929-06-8 CAPLUS
CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(3,5-dimethyl-1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 866929-16-0 CAPLUS
CN Pyridine, 3-bromo-5-(4-chlorophenyl)-2-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866929-19-3 CAPLUS
CN 3-Pyridinamine, 5-(4-chlorophenyl)-2-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866929-27-3 CAPLUS
CN Benzaldehyde, 4-[6-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 866929-35-3 CAPLUS
CN Phenol, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 866929-42-2 CAPLUS
CN Cyclohexanol, 4-methyl-1-[6-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]-3-pyridinyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 866934-41-0 CAPLUS
CN Ethanone, 1-[5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



IT 866928-04-3P 866928-05-4P 866928-06-5P
866928-07-6P 866928-08-7P 866928-10-1P
866928-11-2P 866928-14-5P 866928-15-6P
866928-16-7P 866928-17-8P 866928-18-9P
866928-29-2P 866928-31-6P 866928-32-7P
866928-33-8P 866928-37-2P 866928-39-4P
866928-41-8P 866928-43-0P 866928-45-2P
866928-55-4P 866928-58-7P 866928-63-4P
866928-64-5P 866928-65-6P 866928-66-7P
866928-67-8P 866928-68-9P 866928-69-0P
866928-70-3P 866928-71-4P 866928-72-5P
866928-73-6P 866928-74-7P 866928-75-8P
866928-76-9P 866928-77-0P 866928-78-1P
866928-79-2P 866928-80-5P 866928-81-6P
866928-82-7P 866928-83-8P 866928-88-3P
866928-89-4P 866928-90-7P 866928-91-8P
866928-92-9P 866928-93-0P 866928-94-1P
866928-95-2P 866928-96-3P 866928-97-4P
866928-98-5P 866928-99-6P 866929-00-2P

866929-01-3P 866929-07-9P 866929-08-0P
866929-09-1P 866929-10-4P 866929-11-5P
866929-12-6P 866929-13-7P 866929-14-8P
866929-15-9P 866929-17-1P 866929-18-2P
866929-21-7P 866929-22-8P 866929-23-9P
866929-26-2P 866929-28-4P 866929-29-5P
866929-31-9P 866929-32-0P 866929-33-1P
866929-36-4P 866929-37-5P 866929-41-1P
866929-43-3P 866929-45-5P 866929-46-6P
866929-47-7P 866929-57-9P 866929-58-0P
866931-04-6P 867029-81-0P 867029-82-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted pyridine alkynes with MCH antagonistic activity for treatment of metabolic disorders)

RN 866928-04-3 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]ethoxy]-3-methylphenyl]ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-05-4 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]ethoxy]-3-methylphenyl]ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-06-5 CAPLUS

CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 866928-07-6 CAPLUS
CN 4-Piperidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-α-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 866928-08-7 CAPLUS
CN Ethanone, 1-[1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-piperidinyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)



RN 866928-10-1 CAPLUS
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-(trifluoromethyl)-, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-11-2 CAPLUS
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-

methylphenoxy]ethyl]-4-(trifluoromethyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-14-5 CAPLUS
CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 866928-15-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-3-methyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 866928-16-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-3-ethyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 866928-17-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-3-(trifluoromethyl)-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 866928-18-9 CAPLUS
CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-ethyl- (9CI) (CA INDEX NAME)



RN 866928-29-2 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-31-6 CAPLUS
CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 866928-32-7 CAPLUS
CN 4-Piperidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-α-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 866928-33-8 CAPLUS
CN Ethanone, 1-[1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-piperidinyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)



RN 866928-37-2 CAPLUS
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-(trifluoromethyl)-, (3S,4R)- (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



RN 866928-39-4 CAPLUS
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-(trifluoromethyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-41-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-3-methyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 866928-43-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-3-ethyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 866928-45-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-3-(trifluoromethyl)-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 866928-55-4 CAPLUS
CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 866928-58-7 CAPLUS
CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-ethyl- (9CI) (CA INDEX NAME)



RN 866928-63-4 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-64-5 CAPLUS
CN Pyridine, 2-[[4-[2-(1-azetidinyl)ethoxy]phenyl]ethynyl]-5-(4-chlorophenyl)-3-fluoro- (9CI) (CA INDEX NAME)



RN 866928-65-6 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-3-fluoro-2-[[4-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-66-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 866928-67-8 CAPLUS
CN 4-Piperidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 866928-68-9 CAPLUS
CN 3-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 866928-69-0 CAPLUS
CN 3,4-Piperidinediol, 1-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-methyl-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-70-3 CAPLUS
CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 866928-71-4 CAPLUS
CN Cyclopropanol, 1-[(2S)-1-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-72-5 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-73-6 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-3-fluoro-2-[[4-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]ethoxy]-3-methylphenyl]ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-74-7 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-3-fluoro-2-[[3-methyl-4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866928-75-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 866928-76-9 CAPLUS
CN Cyclopropanol, 1-[(2S)-1-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-77-0 CAPLUS
CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 866928-78-1 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[2-[2-bromo-4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-79-2 CAPLUS
CN Cyclopropanol, 1-[(2S)-1-[2-[2-bromo-4-[[5-(4-chlorophenyl)-3-fluoro-2-

pyridinyl]ethynyl]phenoxy]ethyl]-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-80-5 CAPLUS
CN Pyridine, 2-[[3-bromo-4-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]ethoxy]phenyl]ethynyl]-5-(4-chlorophenyl)-3-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-81-6 CAPLUS
CN 4-Piperidinol, 1-[2-[2-bromo-4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 866928-82-7 CAPLUS
CN Pyridine, 2-[[3-bromo-4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]-5-(4-chlorophenyl)-3-fluoro- (9CI) (CA INDEX NAME)



RN 866928-83-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-[2-bromo-4-[[5-(4-chlorophenyl)-3-fluoro-2-pyridinyl]ethynyl]phenoxy]ethyl]-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 866928-88-3 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[3-ethenyl-4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866928-89-4 CAPLUS
CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-ethenylphenoxy]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 866928-90-7 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-ethenylphenoxy]ethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-91-8 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(4,4-dimethyl-1-piperidinyl)ethoxy]-3-ethenylphenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866928-92-9 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[3-(1-methylethenyl)-4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866928-93-0 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-(1-methylethenyl)phenoxy]ethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-94-1 CAPLUS
CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-(1-methylethenyl)phenoxy]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 866928-95-2 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(4,4-dimethyl-1-piperidinyl)ethoxy]-3-(1-methylethenyl)phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866928-96-3 CAPLUS
CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-(1-methylethenyl)phenoxy]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 866928-97-4 CAPLUS
CN Ethanone, 1-[5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]ethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866928-98-5 CAPLUS
CN Ethanone, 1-[5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(4-hydroxy-4-methyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 866928-99-6 CAPLUS
CN Ethanone, 1-[5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(4,4-dimethyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 866929-00-2 CAPLUS
CN Ethanone, 1-[5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-[4-hydroxy-4-(trifluoromethyl)-1-piperidinyl]ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 866929-01-3 CAPLUS
CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(4-methyl-1-piperidinyl)ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 866929-07-9 CAPLUS
CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 866929-08-0 CAPLUS
CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(4-hydroxy-1-piperidinyl)ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 866929-09-1 CAPLUS
CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(2,6-dimethyl-1-piperidinyl)ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 866929-10-4 CAPLUS
CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(3,5-dimethyl-1-piperidinyl)ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 866929-11-5 CAPLUS
CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(4-methyl-1-piperidinyl)ethoxy]-, oxime (9CI) (CA INDEX NAME)



RN 866929-12-6 CAPLUS
CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]ethoxy]-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 866929-13-7 CAPLUS
CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(4-hydroxy-1-piperidinyl)ethoxy]-, oxime (9CI) (CA INDEX NAME)



RN 866929-14-8 CAPLUS
CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(2,6-dimethyl-1-piperidinyl)ethoxy]-, oxime (9CI) (CA INDEX NAME)



RN 866929-15-9 CAPLUS
CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(3,5-dimethyl-1-piperidinyl)ethoxy]-, oxime (9CI) (CA INDEX NAME)



RN 866929-17-1 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-3-methyl-2-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866929-18-2 CAPLUS
CN Pyridine, 3-methyl-5-(4-methylphenyl)-2-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866929-21-7 CAPLUS
CN Pyridine, 3-chloro-5-(4-chlorophenyl)-2-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866929-22-8 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[2-[4-[[3-chloro-5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866929-23-9 CAPLUS
CN 4-Piperidinol, 1-[2-[4-[[3-chloro-5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 866929-26-2 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[3-ethyl-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866929-28-4 CAPLUS
CN Benzenemethanol, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-α-methyl-2-[2-(1-pyrrolidinyl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 866929-29-5 CAPLUS
CN Benzenemethanol, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-α-methyl-2-[2-(4-methyl-1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 866929-31-9 CAPLUS
CN Pyridine, 5-[4-(difluoromethyl)phenyl]-2-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866929-32-0 CAPLUS
CN Benzenemethanamine, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 866929-33-1 CAPLUS
CN Acetamide, N-[5-(4-chlorophenyl)-2-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 866929-36-4 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[3-propoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866929-37-5 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[3-ethoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866929-41-1 CAPLUS
CN Cyclohexanol, 4-methyl-1-[6-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]-3-pyridinyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 866929-43-3 CAPLUS
CN Benzenemethanol, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(4-methyl-1-piperidinyl)ethoxy]-α-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 866929-45-5 CAPLUS

CN 3-Pyridinamine, 5-(4-chlorophenyl)-N-methyl-2-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866929-46-6 CAPLUS
CN 3-Pyridinamine, 5-(4-chlorophenyl)-N,N-dimethyl-2-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866929-47-7 CAPLUS
CN Pyridine, 5-(4-methyl-1-cyclohexen-1-yl)-2-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866929-57-9 CAPLUS
CN Pyridine, 3-fluoro-5-(4-methyl-1-cyclohexen-1-yl)-2-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866929-58-0 CAPLUS
CN 4-Piperidinol, 1-[2-[4-[[3-fluoro-5-(4-methyl-1-cyclohexen-1-yl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 866931-04-6 CAPLUS
CN Benzenemethanol, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-α-methyl-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 867029-81-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-3-(trifluoromethyl)-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867029-82-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-3-(trifluoromethyl)-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 690265-82-8P, 5-Bromo-2-[(4-[2-(4-methylpiperidin-1-yl)ethoxy]phenyl)ethynyl]pyridine 866930-55-4P, 5-(4-Chlorophenyl)-2-[(3-isopropoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)ethynyl]pyridine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted pyridine alkynes with MCH antagonistic activity for treatment of metabolic disorders)

RN 690265-82-8 CAPLUS
CN Pyridine, 5-bromo-2-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 866930-55-4 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[3-(1-methylethoxy)-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2005:1008939 CAPLUS
DOCUMENT NUMBER:	143:471878
TITLE:	Synthesis of some oligopyridine-galactose conjugates and their metal complexes: a simple entry to multivalent sugar ligands
AUTHOR(S):	Orlandi, Simonetta; Annunziata, Rita; Benaglia, Maurizio; Cozzi, Franco; Manzoni, Leonardo
CORPORATE SOURCE:	Centro di Eccellenza CISI, Dipartimento di Chimica Organica e Industriale, Universita' degli Studi di Milano, Milan, 20133, Italy
SOURCE:	Tetrahedron (2005), 61(42), 10048-10060 CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER:	Elsevier B.V.
DOCUMENT TYPE:	Journal
LANGUAGE:	English
OTHER SOURCE(S):	CASREACT 143:471878

AB Some galactose-oligopyridine conjugates were readily assembled by combining differently functionalized oligopyridines with peracetylated galactose derivs. Variation in the structure of the components and of the linkers employed for their connection afforded adducts of different size, shape, and conformational mobility. Complexation of the bipyridine ligands with CuOTf and of the terpyridine ligand with Zn(OTf)2 afforded the corresponding peracetylated 2:1 and 1:1 complexes, resp., as single species. Their structures are tetrahedral (Cu complexes) and trigonal-bipyramidal (Zn complex), from spectroscopic evidence. Removal of the acetyl protecting groups from the ligands afforded the corresponding polyols. The terpyridine-Zn(II) complex, unlike the bipyridine-Cu(I) complexes maintained their structures upon removal of the acetyl protecting groups.

IT 868992-08-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oligopyridine-galactose conjugates and their copper and zinc complexes)
RN 868992-08-9 CAPLUS
CN β-D-Galactopyranoside, [2,2'-bipyridine]-6,6'-diylbis(2,1-ethynediyl-4,1-phenylene) bis-, 2,2',3,3',4,4',6,6'-octaacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A





IT 868992-11-4P 868992-13-6P 868992-16-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of oligopyridine-galactose conjugates and their copper and zinc complexes)
RN 868992-11-4 CAPLUS
CN β-D-Galactopyranose, [2,2':6',2''-terpyridine]-6,6''-diylbis(2,1-ethynediyl-4,1-phenylene) bis-, 2,2',3,3',4,4',6,6'-octaacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 2-A



RN 868992-13-6 CAPLUS
CN β-D-Galactopyranoside, [2,2'-bipyridine]-6,6'-diylbis(2,1-ethynediyl-4,1-phenylene) bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 868992-16-9 CAPLUS
CN β-D-Galactopyranoside, [2,2':6',2''-terpyridine]-6,6''-diylbis(2,1-ethynediyl-4,1-phenylene) bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:390227 CAPLUS
DOCUMENT NUMBER: 140:406742
TITLE: Preparation of ethynylpyridines and related compounds as melanin-concentrating hormone receptor (MCH-1) antagonist for the treatment of metabolic disorders.
INVENTOR(S): Mueller, Stephan-Georg; Stenkamp, Dirk; Arndt, Kirsten; Roth, Gerald Juergen; Lotz, Ralf Richard Hermann; Lehmann-Lintz, Thorsten; Lenter, Martin; Lustenberger, Philipp; Rudolf, Klaus
PATENT ASSIGNEE(S): Boehringer Ingelheim, Germany
SOURCE: PCT Int. Appl., 361 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039780	A1	20040513	WO 2003-EP11887	20031025
WO 2004039780	A8	20040715		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10250708	A1	20040519	DE 2002-10250708	20021031
CA 2504160	A1	20040513	CA 2003-2504160	20031025
AU 2003300507	A1	20040525	AU 2003-300507	20031025
EP 1558578	A1	20050803	EP 2003-809734	20031025
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014839	A	20050830	BR 2003-14839	20031025
CN 1732154	A	20060208	CN 2003-80102635	20031025
JP 2006511492	T	20060406	JP 2004-547566	20031025
US 2004209865	A1	20041021	US 2003-697443	20031030
NO 2005000749	A	20050523	NO 2005-749	20050211

PRIORITY APPLN. INFO.: DE 2002-10250708 A 20021031
US 2003-456543P P 20030321
WO 2003-EP11887 W 20031025

OTHER SOURCE(S): MARPAT 140:406742

GI



I



II



III

AB Title compds. I [R1, R2 = H, (un)substituted alkyl, cycloalkyl, etc; X = alkyl, alkenyl, alkynyl, etc.; W, Z = alkylene with provisos; Y = Cy with provisos; A = Cy; B = Cy, alkyl, alkenyl, etc.; Cy = (un)subsitiuted carbocycle, heterocycle] and their pharmaceutically acceptable salts and formulations were prepared For example, palladium mediated coupling of bromopyridine II, e.g., prepared from 4-iodophenol in 2-steps, and

4-bromophenylboronic acid afforded claimed ethynylpyridine III in 11% yield. In melanin concentrating hormone receptor (MCH-1R) binding assays, 2-examples of compds. I exhibited IC50 values ranging from 8-74 nM, e.g., the IC50 of ethynylpyridine III was 8 nM. Compds. I are claimed useful for the treatment of metabolic disorders and/or eating disorders, in particular, obesity, bulimia, anorexia, hyperphagia and diabetes.

IT 690262-91-0P 690263-08-2P 690263-15-1P
690263-20-8P 690263-78-6P 690265-45-3P
690266-06-9P 690266-07-0P 690266-10-5P
690266-42-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of ethynylpyridines and related compds. as melanin-concentrating
hormone receptor (MCH-1) antagonist for the treatment of metabolic disorders.)

RN 690262-91-0 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[3-methyl-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-08-2 CAPLUS
CN Pyridine, 2-[[3-bromo-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]-5-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 690263-15-1 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-3-fluoro-2-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-20-8 CAPLUS
CN Carbamic acid, [1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 690263-78-6 CAPLUS
CN 4-Piperidinemethanamine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 690265-45-3 CAPLUS
CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 690266-06-9 CAPLUS
CN Carbamic acid, [[1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-piperidinyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OBu-t

RN 690266-07-0 CAPLUS
CN Carbamic acid, [(3R)-1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—OBu-t

RN 690266-10-5 CAPLUS
CN [4,4'-Bipiperidine]-1-carboxylic acid, 1'-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OBu-t

RN 690266-42-3 CAPLUS
CN Carbamic acid, [1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-methyl-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 690262-71-6P 690262-74-9P 690262-75-0P
690262-83-0P 690262-88-5P 690262-89-6P
690262-90-9P 690262-93-2P 690262-94-3P
690263-04-8P 690263-05-9P 690263-09-3P
690263-11-7P 690263-13-9P 690263-14-0P
690263-18-4P 690263-21-9P 690263-22-0P
690263-24-2P 690263-25-3P 690263-28-6P
690263-29-7P 690263-30-0P 690263-31-1P
690263-32-2P 690263-34-4P 690263-35-5P
690263-36-6P 690263-37-7P 690263-38-8P
690263-43-5P 690263-48-0P 690263-49-1P
690263-50-4P 690263-52-6P 690263-53-7P
690263-54-8P 690263-55-9P 690263-57-1P
690263-58-2P 690263-59-3P 690263-60-6P
690263-61-7P 690263-63-9P 690263-65-1P
690263-66-2P 690263-67-3P 690263-68-4P
690263-69-5P 690263-70-8P 690263-72-0P
690263-73-1P 690263-74-2P 690263-76-4P
690263-77-5P 690263-79-7P 690263-81-1P
690263-85-5P 690263-88-8P 690263-94-6P
690264-06-3P 690264-07-4P 690264-08-5P
690264-09-6P 690264-32-5P 690264-38-1P
690264-44-9P 690264-48-3P 690264-54-1P
690264-57-4P 690264-61-0P 690264-63-2P
690264-69-8P 690265-20-4P 690265-33-9P
690265-39-5P 690265-77-1P 690265-81-7P
690265-83-9P 690265-99-7P 690266-02-5P
690266-03-6P 690266-08-1P 690266-09-2P
690266-12-7P 690266-13-8P 690266-14-9P
690266-15-0P 690266-16-1P 690266-17-2P
690266-20-7P 690266-21-8P 690266-22-9P
690266-24-1P 690266-25-2P 690266-29-6P
690266-30-9P 690266-32-1P 690266-33-2P
690266-34-3P 690266-35-4P 690266-36-5P
690266-39-8P 690266-40-1P 690266-41-2P
690266-43-4P 690266-44-5P 690266-45-6P
690266-46-7P 690266-47-8P 690266-48-9P
690266-49-0P 690266-50-3P 690266-52-5P
690266-53-6P 690266-54-7P 690266-55-8P
690267-33-5P 690267-34-6P 690267-35-7P
690267-36-8P 690267-37-9P 690267-38-0P
690267-39-1P 690267-40-4P 690267-41-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ethynylpyridines and related compds. as melanin-concentrating
hormone receptor (MCH-1) antagonist for the treatment of metabolic disorders.)

RN 690262-71-6 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 690262-74-9 CAPLUS
CN 4-Piperidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 690262-75-0 CAPLUS
CN 3-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 690262-83-0 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(4-propyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690262-88-5 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(2,6-dimethyl-1-piperidinyl)ethoxy]-3-methylphenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690262-89-6 CAPLUS
CN Benzoic acid, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 690262-90-9 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[3-methyl-4-[2-(1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690262-93-2 CAPLUS
CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 690262-94-3 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[3-methyl-4-[2-[2-(1-pyrrolidinylmethyl)-1-piperidinyl]ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-04-8 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 690263-05-9 CAPLUS
CN Benzenamine, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 690263-09-3 CAPLUS
CN 1H-Azepine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]hexahydro- (9CI) (CA INDEX NAME)



RN 690263-11-7 CAPLUS
CN Benzamide, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-N-methyl-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 690263-13-9 CAPLUS
CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 690263-14-0 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[3-methyl-4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-18-4 CAPLUS
CN 4-Piperidineacetic acid, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 690263-21-9 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-22-0 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-24-2 CAPLUS
CN Pyridine, 2-[[4-[2-(1-azetidinyl)ethoxy]phenyl]ethynyl]-5-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 690263-25-3 CAPLUS
CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 690263-28-6 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[3-chloro-4-[2-(1-

pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-29-7 CAPLUS
CN 3-Pyrrolidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 690263-30-0 CAPLUS
CN 2-Pyridinamine, N-[1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 690263-31-1 CAPLUS
CN Pyridine, 5-(4-bromophenyl)-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-32-2 CAPLUS
CN Acetamide, N-[[1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-piperidinyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 690263-34-4 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(4-ethyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-35-5 CAPLUS
CN 4-Piperidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 690263-36-6 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-37-7 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(3,6-dihydro-1(2H)-pyridinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-38-8 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(2-methyl-1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-43-5 CAPLUS
CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 690263-48-0 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[3-methyl-4-[2-[4-(2-pyridinyloxy)-1-piperidinyl]ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-49-1 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(3,6-dihydro-1(2H)-pyridinyl)ethoxy]-3-methylphenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-50-4 CAPLUS
CN 3-Pyrrolidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 690263-52-6 CAPLUS
CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 690263-53-7 CAPLUS
CN 4-Piperidinol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 690263-54-8 CAPLUS
CN Pyridine, 2-[[4-(2-[4,4'-bipiperidin]-1-ylethoxy)phenyl]ethynyl]-5-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 690263-55-9 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[3-ethynyl-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-57-1 CAPLUS
CN 4-Piperidinamine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 690263-58-2 CAPLUS
CN Benzaldehyde, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy]-, oxime (9CI) (CA INDEX NAME)



RN 690263-59-3 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(2,6-dimethyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-60-6 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-[4-(1H-imidazol-4-yl)-1-piperidinyl]ethoxy]-3-methylphenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-61-7 CAPLUS
CN 2-Piperidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 690263-63-9 CAPLUS
CN 4-Piperidinecarboxamide, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 690263-65-1 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-66-2 CAPLUS
CN 4-Piperidineethanamine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-N,N-diethyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—NEt_2

RN 690263-67-3 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(2,4,6-trimethyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-68-4 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(3,5-dimethyl-1-piperidinyl)ethoxy]-3-methylphenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-69-5 CAPLUS
CN Isoquinoline, 2-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]decahydro-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 690263-70-8 CAPLUS
CN 2,6-Diazaspiro[3.4]octane, 6-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 690263-72-0 CAPLUS
CN 3-Pyrrolidinamine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 690263-73-1 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[3-fluoro-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-74-2 CAPLUS
CN 4-Piperidinamine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-N-cyclopentyl-N-methyl- (9CI) (CA INDEX NAME)



RN 690263-76-4 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-[4-(1-pyrrolidinyl)-1-piperidinyl]ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-77-5 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(2,5-dihydro-1H-pyrrol-1-yl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690263-79-7 CAPLUS
CN Piperazine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 690263-81-1 CAPLUS
CN Spiro[piperidine-4,2'(1'H)-quinazolin]-4'(3'H)-one, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 690263-85-5 CAPLUS
CN 3,9-Diazaspiro[5.5]undecane, 3-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-9-methyl- (9CI) (CA INDEX NAME)



RN 690263-88-8 CAPLUS
CN Isoquinoline, 2-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 690263-94-6 CAPLUS
CN Isoquinoline, 2-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]eth
yl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 690264-06-3 CAPLUS
CN Pyridine, 5-(4-fluorophenyl)-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethyny
l]- (9CI) (CA INDEX NAME)



RN 690264-07-4 CAPLUS
CN Pyridine, 2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]-5-[4-
(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 690264-08-5 CAPLUS
CN Pyridine, 5-(4-methoxyphenyl)-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethyn
yl]- (9CI) (CA INDEX NAME)



RN 690264-09-6 CAPLUS
CN Pyridine, 2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]-5-[4-
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 690264-32-5 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[3,5-dimethyl-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690264-38-1 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(1-pyrrolidinyl)ethoxy]-3-(trifluoromethoxy)phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690264-44-9 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(1-pyrrolidinyl)ethoxy]-3-(trifluoromethyl)phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690264-48-3 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[2-chloro-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690264-54-1 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[3-nitro-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690264-57-4 CAPLUS
CN Benzoic acid, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-3-methyl-2-[2-(1-pyrrolidinyl)ethoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 690264-61-0 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[(1-ethyl-3-piperidinyl)oxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690264-63-2 CAPLUS
CN 1-Azabicyclo[2.2.2]octane, 3-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 690264-69-8 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(2,2,6,6-tetramethyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690265-20-4 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[2-fluoro-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690265-33-9 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[1-methyl-2-(1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690265-39-5 CAPLUS
CN Benzonitrile, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 690265-77-1 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[3-(2-pyridinyl)-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690265-81-7 CAPLUS
CN Pyridine, 2-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]-5-phenyl- (9CI) (CA INDEX NAME)



RN 690265-83-9 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(4-methyl-1-piperidinyl)propoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690265-99-7 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 690266-02-5 CAPLUS
CN Morpholine, 4-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 690266-03-6 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 690266-08-1 CAPLUS
CN 2-Piperidinemethanol, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 690266-09-2 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(2-ethyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690266-12-7 CAPLUS
CN 2-Piperidineethanamine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 690266-13-8 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(4-phenyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690266-14-9 CAPLUS
CN 2-Piperidinecarboxamide, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 690266-15-0 CAPLUS
CN 4H-Thieno[2,3-d]azepine, 6-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)



RN 690266-16-1 CAPLUS
CN Quinoline, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]

decahydro- (9CI) (CA INDEX NAME)



RN 690266-17-2 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(3,5-dimethyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690266-20-7 CAPLUS
CN 3-Piperidinamine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 690266-21-8 CAPLUS
CN 4-Piperidinemethanamine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 690266-22-9 CAPLUS
CN 3-Pyrrolidinamine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 690266-24-1 CAPLUS
CN Proline, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 690266-25-2 CAPLUS
CN 4-Piperidinemethanamine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]phenoxy]ethyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 690266-29-6 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(2,5-dihydro-1H-pyrrol-1-yl)ethoxy]-3-methylphenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690266-30-9 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[3-methyl-4-[2-[4-(1-methylethyl)-1-piperidinyl]ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690266-32-1 CAPLUS
CN 1H-1,4-Diazepine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)



RN 690266-33-2 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[3-methyl-4-[2-[2-(1-methylethyl)-1-pyrrolidinyl]ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690266-34-3 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[3-methyl-4-[2-[2-(phenylmethyl)-1-pyrrolidinyl]ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690266-35-4 CAPLUS
CN 4-Piperidinone, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 690266-36-5 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(2,2-dimethyl-3-phenyl-1-pyrrolidinyl)ethoxy]-3-methylphenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690266-39-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 690266-40-1 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[4-[2-(3,3-dimethyl-1-piperidinyl)ethoxy]-3-methylphenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690266-41-2 CAPLUS
CN Piperazine, 1-acetyl-4-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 690266-43-4 CAPLUS
CN Methanesulfonamide, N-[1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 690266-44-5 CAPLUS
CN 4-Piperidinebutanoic acid, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— OMe

RN 690266-45-6 CAPLUS
CN 4-Piperidinamine, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 690266-46-7 CAPLUS
CN 1,2-Ethanediamine, N'-[1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-

methylphenoxy]ethyl]-4-piperidinyl]-N,N-diethyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 690266-47-8 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine], 1'-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-1,2-dihydro-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 690266-48-9 CAPLUS
CN 1H-Isoindole, 2-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 690266-49-0 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 690266-50-3 CAPLUS
CN Pyridine, 5-(4-chlorophenyl)-2-[[3-methyl-4-[2-[4-(trifluoromethyl)-1-piperidinyl]ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690266-52-5 CAPLUS
CN 4-Piperidinone, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, oxime (9CI) (CA INDEX NAME)



RN 690266-53-6 CAPLUS
CN 4-Piperidinone, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 690266-54-7 CAPLUS

CN Pyridine, 5-(4-chlorophenyl)-2-[[3-methyl-4-[2-[3-(1-piperidinyl)-1-azetidinyl]ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690266-55-8 CAPLUS
CN 3-Piperidinecarboxamide, 1-[2-[4-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-methylphenoxy]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 690267-33-5 CAPLUS
CN Benzoic acid, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 690267-34-6 CAPLUS
CN Benzamide, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-N,N-dimethyl-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 690267-35-7 CAPLUS
CN Benzamide, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 690267-36-8 CAPLUS
CN Benzamide, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-N-cyclopropyl-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)





RN 690267-37-9 CAPLUS
CN Benzamide, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 690267-38-0 CAPLUS
CN Acetamide, N-[5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-

pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 690267-39-1 CAPLUS
CN Methanesulfonamide, N-[5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-2-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 690267-40-4 CAPLUS
CN Benzenamine, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-N,N-dimethyl-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 690267-41-5 CAPLUS
CN Benzenamine, 5-[[5-(4-chlorophenyl)-2-pyridinyl]ethynyl]-N-methyl-2-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



IT 690264-05-2P 690265-82-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of ethynylpyridines and related compds. as melanin-concentrating
hormone receptor (MCH-1) antagonist for the treatment of metabolic disorders.)

RN 690264-05-2 CAPLUS
CN Pyridine, 5-bromo-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 690265-82-8 CAPLUS
CN Pyridine, 5-bromo-2-[[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:403795 CAPLUS
DOCUMENT NUMBER: 139:130257
TITLE: A europium chelate for quantitative point-of-care immunoassays using direct surface measurement
AUTHOR(S): von Lode, Piia; Rosenberg, Jaana; Pettersson, Kim; Takalo, Harri
CORPORATE SOURCE: Department of Biotechnology, University of Turku, Turku, FIN-20520, Finland
SOURCE: Analytical Chemistry (2003), 75(13), 3193-3201
CODEN: ANCHAM; ISSN: 0003-2700
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB New labels and assay techniques are needed to improve the sensitivity and quantitativeness of point-of-care immunotesting while sustaining the rapidity and ease of use of the assays. We synthesized a novel, intrinsically fluorescent nonadentate europium chelate with two chromophores and hydrophilic α-galactose side groups. The chelate is highly fluorescent, soluble in water, and provides effective shielding of Eu from water. The performance of the nonadentate chelate was compared with a heptadentate chelate in a dry reagent immunoassay for human chorionic gonadotropin (hCG). After 15-min incubation and washing, time-resolved fluorescence was measured directly from a wet or dried well surface. Contrary to the heptadentate label, the effect of aqueous quenching on the nonadentate label was found to be insignificant, with calculated anal. detection limits (background + 3 SD) of 0.9 and 0.7 IU/L hCG for wet and dry measurements, resp., and a linear range up to 5000 IU/L. The CVs for the new label were <8% at the cutoff of 25 IU/L and above in both whole blood and plasma. The novel nonadentate label facilitates short

turnaround times and simple instrumentation due to the absence of all signal development steps, at the same time retaining an excellent immunoassay performance.

IT 565230-36-6P 565230-37-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(europium chelate for quant. point-of-care immunoassays using direct surface measurement)

RN 565230-36-6 CAPLUS

CN Glycine, N,N'-[[[2-(4-aminophenyl)ethyl]imino]bis[methylene[4-[[4-[(2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl)oxy]phenyl]ethynyl]-6,2-pyridinediyl]methylene]]bis[N-[2-(1,1-dimethylethoxy)-2-oxoethyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 565230-37-7 CAPLUS
CN Glycine, N,N'-[[[2-(4-aminophenyl)ethyl]imino]bis[methylene[4-[[4-[(2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl)oxy]phenyl]ethynyl]-6,2-pyridinediyl]methylene]]bis[N-(carboxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:694357 CAPLUS
DOCUMENT NUMBER: 125:317360
TITLE: Use of retinoids for the manufacture of a medicament for the treatment of restenosis
INVENTOR(S): Davies, Peter A. J.; Chandraratna, Roshantha A.; Benedict, Claude R.
PATENT ASSIGNEE(S): Allergan, USA; Board of Regents
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9629069	A1	19960926	WO 1996-US3749		19960319
W: AU, CA, JP					
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
CA 2215731	A1	19960926	CA 1996-2215731		19960319
AU 9652565	A	19961008	AU 1996-52565		19960319
AU 712029	B2	19991028			
EP 814799	A1	19980107	EP 1996-908866		19960319
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
JP 11509830	T	19990831	JP 1996-528571		19960319
US 5798372	A	19980825	US 1997-794289		19970203
PRIORITY APPLN. INFO.:			US 1995-407733	A	19950320
			WO 1996-US3749	W	19960319

GI



I

AB A method is provided for preventing or reducing the risk of restenosis following angioplasty by administering a retinoid, such as an RAR-selective retinoid, e.g. I.

IT 176731-71-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(retinoids for treatment of restenosis)

RN 176731-71-8 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[[3-(1,1-dimethylethyl)-4-[(tetrahydro-2H-pyran-2-yl)oxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



IT 176731-70-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(retinoids for treatment of restenosis)

RN 176731-70-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[[3-(1,1-dimethylethyl)-4-[(tetrahydro-2H-pyran-2-yl)oxy]phenyl]ethynyl]-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:467291 CAPLUS

DOCUMENT NUMBER: 125:167797

TITLE: Preparation of [(tetrahydropyranyloxy)phenylethynyl]nicotinates and analogs having retinoid-like biological activity

INVENTOR(S): Song, Tae K.; Chandraratna, Roshantha A.

PATENT ASSIGNEE(S): Allergan, USA

SOURCE: U.S., 15 pp.

CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5534641	A	19960709	US 1994-366173	19941229
WO 9620938	A1	19960711	WO 1995-US15805	19951207
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9644161	A	19960724	AU 1996-44161	19951207
US 5698700	A	19971216	US 1996-656128	19960531
US 5847160	A	19981208	US 1997-923720	19970904

PRIORITY APPLN. INFO.:
US 1994-366173 A 19941229
WO 1995-US15805 W 19951207
US 1996-656128 A3 19960531

GI



I

AB R1ZZ1C.tplbond.CZ2Z3R3 [R1 = 2-tetrahydropyranyl; R3 = H, CO2H, alkoxycarbonyl, CONH2, etc.; Z = O or S; Z1 = (un)substituted phenylene; Z2 = (un)substituted phenylene, -heteroarylene; Z3 = bond, (cyclo)alkylene, alkenylene, alkynylene] were prepared Thus, 3-BrC6H4OH was alkylated with Me3COH and the 3,4-dihydro-2H-pyran etherified product alkynylated by HC.tplbond.CSiMe3 to give, after deprotection, 3,4-(R1O)(Me3C)C6H3C.tplbond.CH. The latter was arylated by Et 6-iodonicotinate to give title compound I which had IC80 of 0.56nmols (sic) against ornithine decarboxylase.

IT 176731-70-7P 176731-71-8P 176731-77-4P
176731-78-5P 180341-45-1P 180341-46-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [(tetrahydropyranyloxy)phenylethynyl]nicotinates and analogs having retinoid-like biol. activity)

RN 176731-70-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[[3-(1,1-dimethylethyl)-4-[(tetrahydro-2H-pyran-2-yl)oxy]phenyl]ethynyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 176731-71-8 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[[3-(1,1-dimethylethyl)-4-[(tetrahydro-2H-

pyran-2-yl)oxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 176731-77-4 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[[4-[(tetrahydro-2H-pyran-2-yl)oxy]-3-tricyclo[3.3.1.13,7]dec-1-ylphenyl]ethynyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 176731-78-5 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[[4-[(tetrahydro-2H-pyran-2-yl)oxy]-3-tricyclo[3.3.1.13,7]dec-1-ylphenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 180341-45-1 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[[4-[(tetrahydro-2H-pyran-2-yl)oxy]phenyl]ethynyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 180341-46-2 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[[4-[(tetrahydro-2H-pyran-2-yl)oxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:229119 CAPLUS
DOCUMENT NUMBER: 124:343128
TITLE: Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
INVENTOR(S): Song, Tae K.; Chandraratna, Roshantha A.
PATENT ASSIGNEE(S): Allergan, Inc., USA
SOURCE: U.S., 16 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 5498795	A	19960312	US 1994-366170		19941229
WO 9620937	A1	19960711	WO 1995-US15804		19951207
W: AU, CA, JP					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
AU 9644160	A	19960724	AU 1996-44160		19951207
PRIORITY APPLN. INFO.:			US 1994-366170	A	19941229
			WO 1995-US15804	W	19951207

OTHER SOURCE(S): MARPAT 124:343128
GI



I



II

AB Compds. of the formula I wherein R1-R3 and R5 independently are H, lower alkyl of 1 to 6 carbons, branched chain alkyl or cycloalkyl of 3 to 15 carbons, lower alkyl substituted cycloalkyl of 3 to 15 carbons; R4 is lower alkyl of 1 to 6 carbons, branched chain alkyl or cycloalkyl of 3 to 15 carbons or lower alkyl substituted cycloalkyl of 3 to 15 carbons; X is S or O; Y is a Ph group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, imidazolyl and oxazolyl, said groups being substituted with the R5 group defined above; A is (CH2)n where n is 0-5, lower branched chain alkyl having 3-6 carbons, cycloalkyl having 3-6 carbons, alkenyl having 2-6 carbons and 1 or 2 double bonds, alkynyl having 2-6 carbons and 1 or 2 triple bonds; B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COOR8, CONR9R10, CH2OH, CH2OR11, CH2OCOR11, CHO, CH(OR12)2, CHOR13O, COR7, CR7(OR12)2, or CR7OR13O, where R7 is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons, R8 is an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5 to 10 carbons, or R8 is Ph or lower alkylphenyl, R9 and R10 independently are hydrogen, an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5-10 carbons, or Ph or lower alkylphenyl, R11 is lower alkyl, Ph or lower alkylphenyl, R12 is lower alkyl, and R13 is divalent alkyl radical of 2-5 carbons, have retinoid-like biol. activity. Thus, e.g., deblocking of Et 4-[2-[[2-t-butyl-1-(2-tetrahydropyranoxy)]-4-phenyl]ethyn-1-yl]benzoate (preparation given) with pyridinium p-toluenesulfonate afforded Et 4-[2-(2-t-butyl-1-hydroxy-4-phenyl)ethyn-1-yl]benzoate (II) which exhibited IC80 = 0.89 nmol for inhibition of 12-O-tetradecanoylphorbol 13-acetate induction of ornithine decarboxylase activity.

IT 176731-70-7P 176731-71-8P 176731-77-4P
176731-78-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biol. activity)

RN 176731-70-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[[3-(1,1-dimethylethyl)-4-[(tetrahydro-2H-pyran-2-yl)oxy]phenyl]ethynyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 176731-71-8 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[[3-(1,1-dimethylethyl)-4-[(tetrahydro-2H-pyran-2-yl)oxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 176731-77-4 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[[4-[(tetrahydro-2H-pyran-2-yl)oxy]-3-tricyclo[3.3.1.13,7]dec-1-ylphenyl]ethynyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 176731-78-5 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[[4-[(tetrahydro-2H-pyran-2-yl)oxy]-3-tricyclo[3.3.1.13,7]dec-1-ylphenyl]ethynyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1993:484524 CAPLUS
DOCUMENT NUMBER: 119:84524
TITLE: Luminescence of europium(III) chelates with 4-(arylethynyl)pyridines as ligands
AUTHOR(S): Takalo, Harri; Hanninen, Elina; Kankare, Jouko
CORPORATE SOURCE: Cent. Biotechnol., Turku, SF-20521, Finland
SOURCE: Helvetica Chimica Acta (1993), 76(2), 877-83
CODEN: HCACAV; ISSN: 0018-019X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Some spectral properties and luminescence intensities of EuIII chelates with 15 4-(arylethynyl)pyridine-2,6-dicarboxylic acids and 11 2,2',2'',2'''-{[4-(arylethynyl)pyridine-2,6-diyl]bis(methylenenitrilo)}tetrakis(acetic acids) were measured both in H2O and EtOH solns. to develop suitable labels for time-resolved luminescence-based bioaffinity assays. Several of the latter ligands and their Eu complexes were prepared for the 1st time. The substitution at the aryl group has a significant effect upon the observed luminescence intensities, excitation wavelengths, and decay consts. of the complexes. Moreover, the changes in the environment cause great variation in those properties of certain EuIII chelates.

IT 148902-66-3D, europium complex
RL: PRP (Properties)
(luminescence of)
RN 148902-66-3 CAPLUS
CN 2,6-Pyridinedicarboxylic acid, 4-[[4-[(tetrahydro-2H-pyran-2-yl)oxy]phenyl]ethynyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1989:154111 CAPLUS
DOCUMENT NUMBER: 110:154111
TITLE: Synthesis of some substituted dimethyl and diethyl 4-(phenylethynyl)-2,6-pyridinedicarboxylates
AUTHOR(S): Takalo, Harri; Kankare, Jouko; Hanninen, Elina
CORPORATE SOURCE: Dep. Chem., Univ. Turku, Turku, SF-20500, Finland
SOURCE: Acta Chemica Scandinavica, Series B: Organic

Chemistry and Biochemistry (1988), B42(7), 448-54
CODEN: ACBOCV; ISSN: 0302-4369
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 110:154111
GI



I

AB 4-(Phenylethynyl)-2,6-pyridinedicarboxlates I (R = substituted Ph, R1 = Me, Et) were prepared by coupling reactions between dialkyl 4-halo-2,6-pyridinedicarboxylates and terminal arylacetylenes in the presence of an organopalladium catalyst and copper(I) iodide in a suitable solvent system. The terminal acetylenes were synthesized from the corresponding aryl halides using either (trimethylsilyl)acetylene or 2-methyl-3-butyn-2-ol followed by deprotection of the triple bond.

IT 119754-30-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 119754-30-2 CAPLUS

CN 2,6-Pyridinedicarboxylic acid, 4-[[4-[(tetrahydro-2H-pyran-2-yl)oxy]phenyl]ethynyl]-, dimethyl ester (9CI) (CA INDEX NAME)



=>